What are biosimilars and are they important?

Drug and Therapeutics Bulletin

Volumn 51, Issue 5, 2013, Pages 57-60

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOSIMILAR AGENT; CETUXIMAB; ERYTHROPOIETIN; ETANERCEPT; HUMAN GROWTH HORMONE; INSULIN ASPART; INSULIN GLARGINE; LONG ACTING INSULIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT VACCINE; RITUXIMAB; TRASTUZUMAB; WART VIRUS VACCINE;

BIOEQUIVALENCE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; ERYTHROCYTE COUNT; GROWTH HORMONE DEFICIENCY; HEALTH CARE POLICY; HUMAN; IMMUNOGENICITY; NEUTROPHIL COUNT; NOTE; PHYSICAL CHEMISTRY; PURE RED CELL ANEMIA; UNITED KINGDOM;

BIOLOGICAL AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUGS, GENERIC; EUROPE; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84877955125     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2013.5.0181     Document Type: Note

References (31)

1. Generic medicines-can quality be assured? DTB 1997; 2: 9-11
2. Joint Formulary Committee. British National Formulary. Edition 65. London: BMJ Group and RPS Publishing, March 2013.
3. Nivestim Solution for injection/infusion. Summary of Product Characteristics, UK. Hospira UK Limited, January 2013.
4. Tevagrastim Solution for injection/infusion. Summary of Product Characteristics, UK. Teva UK Limited, February 2011.
5. Zarzio Solution for injection and infusion. Summary of Product Characteristics, UK. Sandoz Limited, December 2012.
6. Binocrit Solution for injection. Summary of Product Characteristics, UK. Sandoz Limited, October 2010.
7. Retacrit Solution for injection. Summary of Product Characteristics, UK. Hospira UK Limited, November 2012.
8. Omnitrope Solution for injection. Summary of Product Characteristics, UK. Sandoz Limited, March 2012.
9. European Medicines Agency, 2012. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/12/WC500135703.pdf [Accessed 17 April 2013].
10. Andalusian School of Public Health, 2011. The impact of biosimilars entry in the EU market [online]. Available: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.pdf [Accessed 17 April 2013].
11. Shein-Chung C et al. Scientific considerations for assessing biosimilar products. Stat Med 2013; 32: 370-81.
12. Weise M et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-7.
13. European Medicines Agency. Scientific Guidance Documents on biosimilars [online]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp# [Accessed 17 April 2013].
14. Dingermann T et al. Biosimilar monoclonal antibodies: the next frontier. A summary report from a symposium held at EAHP 2012. Eur J Hosp Pharm 2012; 19: 315-7.
15. Medicines and Healthcare products Regulatory Agency. Biosimilar products. Drug Safety Update 2008; 1: 8 [online]. Available http://www.mhra.gov.uk/home/groups/pl-p/documents/publication/con2033918.pdf [Accessed 17 April 2013].
16. The European Commission, 2012. Commission implementing directive 2012/52/ EU of 20 December 2012 laying down measures to facilitate the recognition of medical prescriptions issued in another member state [online]. Available: http://ec.europa.eu/health/cross_border_care/docs/impl_directive_presciptions_2012_en.pdf [Accessed 17 April 2013].
17. National Institute of Health and Clinical Excellence, 2010. Human growth hormone (somatropin) for the treatment of growth failure in children [online]. Available: http://publications.nice.org.uk/human-growth-hormonesomatropin-for-the-treatment-of-growth-failure-in-children-ta188 [Accessed 17 April 2013].
18. Stewart A et al. Addressing the health technology assessment of biosimilar pharmaceuticals. Curr Med Res Opin 2010; 26: 2119-26.
19. Scottish Medicines Consortium, 2010. Biosimilar Medicines [online]. Available: http://www.scottishmedicines.org.uk/About_SMC/Policy_Statements/Biosimilar_Medicines [Accessed 17 April 2013].
20. NHS Scotland, 2013. Scottish Medicines Consortium [online]. Available: http://www.scottishmedicines.org.uk/Home [Accessed 17 April 2013].
21. All Wales Medicines Strategy Group [online]. Available: http://www.wales.nhs.uk/sites3/home.cfm?orgid=371 [Accessed 17 April 2013].
22. European Medicines Agency, 2008. Omnitrope Scientific Discussion [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000607/WC500043692.pdf [Accessed 17 April 2013].
23. European Medicines Agency, 2010. Binocrit Scientific Discussion [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf [Accessed 17 April 2013].
24. European Medicines Agency, 2008. Retacrit EPAR summary for the public [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374.pdf [Accessed 17 April 2013].
25. Wind K. Medicines Procurement Specialist Pharmacist. Personal communication. March 2013.
26. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010; 10: 90-7.
27. Abrahim I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf 2012; 11: 819-40.
28. European Medicines Agency, 2008. Tevagrastim Scientific Discussion [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000827/WC500036667.pdf [Accessed 17 April 2013].
29. European Medicines Agency, 2010. Nivestim Scientific Discussion [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001142/WC500093664.pdf [Accessed 17 April 2013].
30. European Medicines Agency, 2009. Zarzio Scientific Discussion [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000917/WC500046528.pdf [Accessed 17 April 2013].
31. EU Clinical Trials Register [online]. Available: http://www.clinicaltrialsregister.eu/ [Accessed 17 April 2013].